Clovis Oncology raises public offering to $300 million
BOULDER — Clovis Oncology is continuing its success streak, raising its public offering from $250 million to $300 million worth of common stock.
The company’s underwriters exercised their full option to purchase another 511,363 more shares.
The underwritten offering of 3,409,091 is priced at $88 per share.
SPONSORED CONTENT
The many benefits of simple, coordinated healthcare
Kaiser Permanente combines health care and coverage in one connected system to maximize employee health and minimize employer costs.
Net proceeds from the sale will go to corporate purposes, including sales and marketing of Rubraca, the drug that recently had excellent clinical results. The company is planning to expand that drug to Europe if it is approved.
JP Morgan Securities LLC and BofA Merrill Lynch are the joint book-running managers for the offering, while Stifel and SunTrust Robinson Humphrey are co-managers.
BOULDER — Clovis Oncology is continuing its success streak, raising its public offering from $250 million to $300 million worth of common stock.
The company’s underwriters exercised their full option to purchase another 511,363 more shares.
The underwritten offering of 3,409,091 is priced at $88 per share.
Net proceeds from the sale will go to corporate purposes, including sales and marketing of Rubraca, the drug that recently had excellent clinical results. The company is planning to expand that drug to Europe if it is approved.
JP Morgan Securities LLC and BofA Merrill Lynch are the…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
